Klow vs Glow-70: Comparing Two Aesthetic Peptide Blends
Klow and Glow-70 are both multi-peptide research blends targeting fat metabolism and tissue quality, but they combine different compounds through different mechanisms. Here is how they compare.
Klow and Glow-70 are both multi-peptide research blends aimed at fat metabolism and tissue-quality research, but they are built from different compounds and different mechanisms. Klow pairs a GLP-1/GIP incretin agonist with AOD 9604 and a lipotropic complex; Glow-70 pairs three growth-hormone-axis peptides. Below is a mechanistic, side-by-side look at both.
KLOW: A Three-Pathway Fat Metabolism Stack
KLOW (also written K-LOW) is supplied as a single 80mg vial combining three components that each target a different bottleneck in fat metabolism:
- GLP-1/GIP dual agonist (tirzepatide-class): drives satiety, insulin sensitization, and adipocyte apoptosis
- AOD 9604 (the hGH fragment 177-191): activates beta-adrenergic lipolysis directly in adipocytes, independent of the growth hormone receptor
- Lipo-C: a lipotropic complex of methionine, inositol, choline and L-carnitine supporting hepatic fat processing and mitochondrial fatty-acid transport via CPT-1
The design logic is sequential: reduce intake and improve insulin signaling (GLP-1/GIP), mobilize stored triglycerides (AOD 9604), then clear the resulting fatty-acid load through the liver without accumulation (Lipo-C). Full component breakdown is on the KLOW product page.
Glow-70: A Growth-Hormone-Axis Blend
Glow-70 is a single 70mg vial combining three growth-hormone-axis peptides that converge on visceral adipose tissue:
- Tesamorelin: a full-length GHRH analogue, the only FDA-approved GHRH peptide, driving sustained endogenous GH release
- Ipamorelin: a selective GHS-R1a secretagogue that amplifies each GH pulse through a separate receptor pathway
- AOD 9604: the same GH-fragment lipolytic agent used in KLOW, here layered onto an already GH-elevated system
Unlike KLOW, every component in Glow-70 routes back to the growth hormone axis — either by stimulating GH release directly (tesamorelin, ipamorelin) or by acting on the downstream lipolytic pathway that GH engages (AOD 9604). Full component detail is on the Glow-70 product page.
Comparison Table
| KLOW | Glow-70 | |
|---|---|---|
| Core mechanism | Incretin (GLP-1/GIP) signaling + direct lipolysis + hepatic clearance | Growth-hormone-axis stimulation + direct lipolysis |
| Components | GLP-1/GIP agonist, AOD 9604, Lipo-C | Tesamorelin, ipamorelin, AOD 9604 |
| Appetite pathway | Yes (GLP-1/GIP incretin signaling) | No direct appetite mechanism |
| GH-axis involvement | None | Central to two of three components |
| Hepatic support component | Yes (Lipo-C) | No |
| Vial size | 80mg | 70mg |
| Administration | Subcutaneous injection | Subcutaneous injection |
Where the Two Overlap
Both blends include AOD 9604 as their direct lipolytic agent, and both are studied in fat-metabolism and body-composition research. The difference is what surrounds that shared component: KLOW builds an appetite/incretin layer plus a hepatic-clearance layer around it, while Glow-70 builds a growth-hormone amplification layer around it instead.
Because the mechanisms are largely non-overlapping outside of AOD 9604, researchers frequently study them as separate experimental arms rather than substitutes for one another — comparing incretin-driven versus GH-driven approaches to the same fat-metabolism endpoints.
Comparing More Than Two Products
For a broader side-by-side across the full product catalog, including specification and mechanism comparisons beyond these two blends, see the compare tool.
Research Use Only
Both KLOW and Glow-70 are supplied strictly for laboratory and research use. This article does not describe a treatment, does not claim any efficacy outcome, and is not medical advice. Component-level study citations and dosing information for individual compounds are available on the respective linked product pages.
Interested in the peptides discussed in this article?
Browse our full catalog of research-grade peptides or contact us for personalized recommendations.